Immune Response and Vaccines for SARS-CoV-2 Infection

Dear Colleagues,

This Special Issue, entitled "Immune Response and Vaccines for SARS-CoV-2 Infection", will cover all topics relevant to the immune response and vaccines for infectious diseases, particularly SARS-CoV-2. With the recent COVID-19 pandemic, much research has been conducted on this topic. While mRNA has been studied since the 1990s, in recent years, mRNA has generated significant excitement for human use despite the licensure of several veterinary DNA vaccines. Recently, Pfizer and Moderna launched an mRNA vaccine for SARS-CoV-2, which has been administered to people across the globe. DNA and RNA vaccines are faster and cheaper to produce in large quantities than conventional vaccines. On the other hand, conventional vaccines often use "weakened" or "killed" versions of a virus, meaning that laboratories need to produce huge amounts of the virus. They often also include a protein, which is needed to spark a human immune response. However, producing a virus and a viral protein can be time-intensive and expensive. Therefore, this Special Issue will serve as a forum where scientists can share their latest research findings on the immune responses and vaccines related to infectious diseases, particularly SARS-CoV-2. In this Special Issue, original research articles, case studies, editorials, and reviews are welcome.

We look forward to receiving your contributions.

Dr. Shumaila Hanif
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.